Re: Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes

摘要

Margel et al. showed, in a population-based retrospective cohort study, that increasing duration of metformin use among elderly diabetic men (n = 3837) after diagnosis of prostate cancer (PCa) was associated with decreased PCa-specific and all-cause mortality. The adjusted hazard ratio (HR) for PCa-specific mortality was 0.76 for each additional 6 mo of metformin use, whereas the association with all-cause mortality was also significant but declined over time, from an HR of 0.76 in the first 6 mo to 0.93 between 24 mo and 30 mo. There was no correlation between cumulative metformin use before PCa diagnosis and PCa death. The other antidiabetic medications did not decrease PCa mortality.